• Climb Bio presented initial Phase 1 safety data for CLYM116 at the European Renal Association Congress 2026.
• Early results showed the drug was generally well tolerated in healthy volunteers, supporting continued development in IgA nephropathy.
• Additional Phase 1 pharmacokinetic and pharmacodynamic data are scheduled for presentation at a late-summer R&D Spotlight event.
• Partner Beijing Mabworks expects to start dosing IgA nephropathy patients in a Phase 2 study in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606050700PRIMZONEFULLFEED9732233) on June 05, 2026, and is solely responsible for the information contained therein.